Since 2011, 55 companies with a specific focus on medication adherence have joined AngelList, a platform for startups and angel investors. And that is by no means a complete list of the startups emerging in this space or the solutions being developed by companies who have been around a lot longer. Many companies in this industry—and a few companies from outside of the industry—are developing new ways to try to improve adherence. And they are using new technology and unique strategies to do so. To help you keep up with growing list of adherence solutions available to the industry, PM360 found six of the most recent ones that you may want to look into.
Rachel De Jesus
Vice President Strategy & Partnerships
The key function of Nomi is to facilitate the patient medication journey by adding technology to provide the right care for each patient in an even more tailored and efficient way. Nomi streamlines the communication between the specialty pharmacy, support services, prescriber, and the patient. Nomi uses the data collected from patients to feed and trigger other systems to improve operational efficiencies.
Nomi tracks how patients take their medication in real-time and finds patterns when patients need help. She influences patients unable to correctly take medication through a portfolio of automated and tailored text messages sent directly to patients. Nomi handles complex regimens such as dose titrations, cyclical therapies, pauses, and reductions to coordinate care. Nomi impacts medication-taking habits so that patients feel better, have more confidence, and achieve the desired outcome.
Nomi also communicates with a patient’s family members, other caregivers, and clinical teams. Clinical teams receive escalations and alerts from Nomi to reach out to the patients needing additional clinical assistance and/or education.
In addition, Nomi requires no patient set up. The patient does not have to turn the bottle on, charge it, or pair it with Bluetooth/WIFI. Patients get a new bottle with every fill, so they never have to move medication from one bottle into another. While the SMRxT bottle is the most widely used device, the platform is device agnostic. Nomi works with ingestible capsules, nebulizers, inhalers, injectables, as well as other bottle and cap devices.
Nomi is able to change patient behavior, through system interventions, at least 40% of the time. Nomi also has an average patient response rate of 60%, with some programs getting upwards of 90% patient engagement.
VP Market and Commercial Development
The Medocity Platform enables coordinated, continuous patient-centric care “between visits,” when patients are not with their doctor, by empowering them with medication reminders and a virtual pillbox to promote adherence, interactive symptom management tools, personalized guidance, educational self-care resources, and most importantly, real-time connectivity with their care team. The platform captures and analyzes patient-reported data, detects escalating symptoms in advance, sends out alerts to clinicians, and facilitates care coordination across different disciplines and locations with shared visibility to patients’ symptoms, vital signs, and adherence to medications.
Patients and providers interact through the integrated telehealth suite featuring secure messaging, digital assistants, and real-time video visits. Accessible from any device or operating system, the platform integrates with EMRs and hundreds of connected devices to enable greater visibility, meaningful interactions, and improved coordination of care outside the hospital or clinic.
Medocity’s technology combines multiple virtual care capabilities—condition management, remote monitoring, AI, and telehealth interventions—into one enterprise-level solution. The platform is fully modular, highly configurable, and is accessible on any computer, mobile device, and even traditional landlines. The approach is clinically proven to drive high engagement, improved medication adherence, and better patient outcomes.
For example, during a recent study with Carter Health Psychiatry & Wellness, a Texas-based medical practice, patients exhibited compliance scores averaging 90% to 95% along with notable improvements in mood, anxiety, and depression symptoms. During the 90-day study, patient satisfaction and engagement were also high with 90% using the platform three or more times per week.
Senior VP & COO
HandsFree Health’s WellBe is new a voice-controlled virtual assistant, enabling consumers to personally manage their health from the comfort of their home in a HIPPA-compliant environment. While voice assistants are one of the fastest-growing consumer technology trends in the home, healthcare is just beginning to implement this technology and HandsFree Health is dedicated to the healthcare market. WellBe makes it easy to integrate healthcare into our daily lives while also addressing some of the primary barriers to prescription adherence, which has been a complex and difficult problem for the healthcare system to solve.
WellBe helps address time management issues such as forgetfulness and lack of routine by providing a simple form of communication, integrated into the home, that makes it easy for consumers to seek out answers and set up reminders. In addition, patients can be prompted for timely prescription refills, reminders to administer medicine, learn about cost alternatives for prescriptions, and better understand the proper use and side effects. WellBe can also help bridge an information gap where there is a lack of knowledge with a database about proper use and side effects. HandsFree Health can also work with employers and health plans to tailor programs to their employee or plan member’s needs.
Furthermore, HandsFree Health integrates the latest artificial intelligence (AI) technology to enhance usability. As recently announced at Microsoft BUILD, in addition to typing in prescription information in the app, patients can also take pictures of prescription bottles and have those medications automatically added to prompt refills. Alerts can also notify a patient’s physician or caregiver of a missed dose.
Lash Group Collaborations with AllazoHealth and Medisafe
Shanna Barnes, MHA
Vice President, New Business Development
According to the Annals of Internal Medicine, more than 30% of prescriptions go unfilled. And, even the 70% of patients who do fill a prescription often fall off therapy in the first few months. Lash Group recently entered into two collaborations that leverage AI and predictive analytic technology to address patient needs, increase speed to therapy, and improve adherence.
Lash Group engaged with AllazoHealth to become the first HUB services provider using individualized patient predicted risk and machine learning to provide interventions that are unique to patient behaviors and treatment plans. Leveraging the AllazoEngine AI platform, Lash Group recommends a specific intervention type and cadence, such as motivational text messages, multichannel dosage reminders, and/or targeted clinician touchpoints. The AllazoEngine is the only AI platform validated through peer-reviewed Randomized Control Trial, which proved 5.5x greater adherence compared to traditional programs.
The company also collaborated with Medisafe, a medication management platform, to integrate the Medisafe mobile application into its technology ecosystem. Lash Group patients can now benefit from dosage and refill reminders via the Medisafe app, creating an end-to-end solution that combines digital alerts with human support from licensed clinicians. The collaboration engages patients after therapy is prescribed, but before they first fill a prescription, by creating visibility into the approval and shipment status. Medisafe’s research shows that refill rates for its users are as much as 17% higher than for those not using the app.
Using different methodologies, each solution successfully identifies patients “at-risk” of non-adherence, enabling Lash Group’s nurses to step in and offer support sooner.
CEO and Co-founder
HealthPrize introduced its new product, Drive, in April 2019, to streamline the development and management of branded patient engagement, education, and adherence programs for pharmaceutical brands. Based on hundreds of millions of interactions with patients, Drive applies HealthPrize’s proven approach of gamification, behavioral economics, and loyalty marketing to improve patients’ education about and adherence to their prescribed medications.
Adherence programs developed using HealthPrize’s technology consistently deliver mean adherence lifts of 52% across a broad range of drugs, diseases, demographics, and delivery methods (i.e., 44% lift for a topical acne medication; 58% lift for an inhaled COPD medication; 53% for an injectable diabetes medication; 66% for an oral hypertension medication).
Drive enables pharmaceutical marketers to easily and effectively build a branded adherence program configured to their medications’ unique requirements, patient challenges, and business needs in a few short months, on a proven, proprietary platform. Advanced capabilities in programs built with Drive include:
- Personalized content journey and actionable behavioral triggers configured to the product’s dosing schedule, patient challenges, and business goals.
- Robust messaging segmentation based on patient attributes such as therapy experience level, insurance type, or demographics.
- Interactive program performance dashboards, enhanced data capture, and analysis capabilities.
- Full integration with copay savings card and other third-party data suppliers to ensure validated results.
- Self-service targeted survey capabilities to gather deep patient insights.
Drive is available in three service/pricing tiers to provide flexibility for pharmaceutical brands of all sizes, from specialty medications for rare diseases to medications for broad-reaching primary care conditions. The product can support multiple brands and languages and is fully HIPAA compliant and HITRUST certified.
Natural Language Processing (NLP) Adherence Solution
Director, New Business
Cardinal Health Sonexus™ Access and Patient Support
Cardinal Health Sonexus™ Access and Patient Support is introducing a Natural Language Processing (NLP) adherence solution that leverages NLP technology to derive deeper insights from recorded discussions between the hub services team and providers and patients. The insights gleaned from these calls can enable pharmaceutical brand teams to answer key questions such as: Are there specific times when patients are more likely to experience adverse events—and therefore be at higher risk of falling off therapy? Are there early warning signs of complications that could lead to a hospital readmission? Are there quality-of-life issues that patients experience on therapy that may interfere with adherence? Enabling brand teams to leverage data from their hub-based interactions can result in a better understanding of treatment trends and potential barriers to patient adherence—which in turn can lead to more effective interventions.